Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.
about
Receptor-binding domain-based subunit vaccines against MERS-CoVCurrent advancements and potential strategies in the development of MERS-CoV vaccinesCrystal Structure of the Receptor-Binding Domain from Newly Emerged Middle East Respiratory Syndrome CoronavirusStructure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitorSevere acute respiratory syndrome coronavirus as an agent of emerging and reemerging infectionHuman monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutantsYeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate.Receptor-binding domain as a target for developing SARS vaccines.Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines.A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate.A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike proteinIdentification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development.Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody.Identifying epitopes responsible for neutralizing antibody and DC-SIGN binding on the spike glycoprotein of the severe acute respiratory syndrome coronavirus.Human CD4(+) memory T-lymphocyte responses to SARS coronavirus infection.Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirusNeutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technologyA conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein.A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses.A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunitySingle amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain.The spike protein of SARS-CoV--a target for vaccine and therapeutic development.The epitope and neutralization mechanism of AVFluIgG01, a broad-reactive human monoclonal antibody against H5N1 influenza virus.Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design.Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients.False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid-based western blot assay were rectified by the use of two subunits (S1 and S2) of spike for detection of antibody to SARS-CoV.Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizingA critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection.The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents.Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response.Receptor recognition mechanisms of coronaviruses: a decade of structural studies.Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus.Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.Chicken heat shock protein 90 is a component of the putative cellular receptor complex of infectious bursal disease virusSARS vaccine developmentProtective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV InfectionSevere acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine.Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention.Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions.
P2860
Q26851979-492039C1-F34C-4A11-AB1E-F1B779F057F7Q27012578-FC0D7F1B-F326-4C58-B03B-30D20526064DQ27679307-36D83331-FA9C-46F8-9DB3-1BBEE518A054Q27689029-BA667925-44E5-4365-911A-9386478001AAQ28383088-0AE3156D-6D51-4815-BD4B-A04042BCD990Q28768526-A9DB3340-0D01-46CC-949D-58AFB927F49CQ30218075-EA36FB1A-1060-48B5-94EF-2D23DB21D371Q30353170-6F183F11-B476-4A65-877F-AB04C994073EQ30359335-F827B04E-E28B-4039-B905-60A121B55768Q30378994-010D3181-5EE7-458B-A151-0078AC94C488Q30401512-3694D8E0-C52D-46E5-84F5-1F2610498ACAQ30402347-36BDAB62-39DD-491C-9EA3-A9F4C1A0C3E9Q30432706-34D4094E-4C97-42CB-B59E-643C5E62B7FCQ33239031-A98592EE-B665-472F-B67F-C4D44113AA4BQ33260408-D1441BA7-C751-43D4-AF08-AFDC40572A96Q33293891-5559809A-C2A5-4FA2-A8D2-F9F5F2DB07D7Q33678943-E05A25FD-4B00-4622-8D39-273B063DA5D2Q33688229-A4EFCD15-BDD8-4DD8-8D6B-935C147AA53FQ33743790-E3252A7A-31A3-4F4F-A68C-F0187A444452Q33815195-64D8733D-656C-41C9-8548-724155BCA812Q33904997-A4ACD190-F2CB-4A18-9910-CE42E0BC9EFAQ33987417-E83DC698-94FA-4CA4-8E5E-AFDA9C5D657DQ34015988-44015B06-5B18-4F42-BCAD-CE4A9802E165Q34291530-E38F7AA6-4C90-4951-9338-F34D3B156932Q34324907-CB763DF9-8EC1-4F81-A729-DF46111D1CD0Q34332142-FDAF3304-5393-43A7-8BCA-E1DC1F3BDBA2Q34429423-EBF78F5A-136D-4A08-B4FC-1AC8CF593E46Q34491357-EE6850A8-09EE-4832-9401-4549483E7DA4Q34548282-1C616A0A-50D2-43AD-99DA-621DCABB55DEQ34652511-95320D30-79FA-49FB-BBBA-7A3774114824Q35076795-7B269022-A1A9-4080-826E-DFDD222820C8Q35115572-B849F9BB-2F55-4A69-B798-715BCCD9B0B3Q35857387-3767636D-D992-431D-8022-0B611A9C349BQ35901171-B4F001F3-5113-40E5-8E51-F6EB58D56922Q35947841-0FC735F4-AA1B-4073-B53A-3A3B80448E72Q36021976-82AC6CCC-4D40-48D3-9E0C-D4B96730D3F1Q36306931-4C946E13-032D-4D0B-A767-938ACAAD5397Q36414621-4DA7C318-44EF-450C-895B-8AB8ECA9B6C5Q36415424-E83C7CEC-B02C-4494-8719-CD6D8F2E5B7DQ36447896-BD6BC083-74FA-4EA3-AFC4-836DE4583006
P2860
Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Receptor-binding domain of sev ...... otent neutralizing antibodies.
@en
type
label
Receptor-binding domain of sev ...... otent neutralizing antibodies.
@en
prefLabel
Receptor-binding domain of sev ...... otent neutralizing antibodies.
@en
P2093
P1476
Receptor-binding domain of sev ...... otent neutralizing antibodies.
@en
P2093
Pamela Siddiqui
Yusen Zhou
P304
P356
10.4049/JIMMUNOL.174.8.4908
P407
P50
P577
2005-04-01T00:00:00Z